TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3150126

Group type: EXPERIMENTAL
Intervention: Magnesium Valproate (Mg VPA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sodium Valproate (Na VPA)
Number of subjects: 122
Study: 31153497

Group type: EXPERIMENTAL
Intervention: Flash-free ceramic bracket
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-flash-free ceramic bracket
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-flash-free metal bracket
Number of subjects: 18
Study: 28129518

Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 61
Study: 25595308

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard fluid therapy (Control)
Number of subjects: 80
Study: 23750460

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment based on exposure exercises (ICBT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Internet-delivered stress management (ISM)
Number of subjects: 195
Study: 21915490

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (12-week stimulation and psychoeducational program, administered twice a week during 6.5-hour gatherings)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (waiting list for future intervention)
Number of subjects: 41
Study: 19589303

Group type: EXPERIMENTAL
Intervention: STAR total ankle replacement (Pivotal Study)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: STAR total ankle replacement (Continued Access Group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Ankle fusion (Pivotal Study)
Number of subjects: 158
Study: 17036357

Group type: EXPERIMENTAL
Intervention: CMR performed on 51 patients (42.9%) at a mean of 2.7+/‐3.1 days after stent implantation (CMR+ group)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (CMR- group) with 68 patients (57.1%)
Number of subjects: 119
Study: 12572939

Group type: EXPERIMENTAL
Intervention: Interferon-omega (2.5 million units/kg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Interferon-omega (2.5 million units/kg) in unvaccinated cohort
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo in unvaccinated cohort
Number of subjects: 94
Study: 11127852

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9485969

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpregnant women in right lateral position
Number of subjects: 30
Study: 16358395

Group type: EXPERIMENTAL
Intervention: High-fat diet (83.5 +/- 3.6% of total energy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (83.1 +/- 3.7% of total energy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 7
Study: 3391420

Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 192

Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 192
Study: 30450213

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) on a cycle ergometer, thrice weekly for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly contact with investigators
Number of subjects: 40
Study: 27214263

Group type: EXPERIMENTAL
Intervention: Nordic Walking with poles (WP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal Walking without poles (NP)
Number of subjects: 17
Study: 25620607

Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation (HVES)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous short wave diathermy
Number of subjects: 15
Study: 23877339

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m², 2-5 min intravenous on days 1 and 8)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ixabepilone (40 mg/m², 3 h intravenous on day 1)
Number of subjects: 104
Study: 19919966

Group type: EXPERIMENTAL
Intervention: Home orthostatic training (HOT) for 40 min daily for 6 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham training for 10 min daily for 6 months
Number of subjects: 22
Study: 18426147

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS) plus loratadine, 200 microg + 10 mg
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS), 200 microg
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 16682384

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel 300 mg, and Tirofiban)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel 600 mg)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 328
Study: 22186694

Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses (n = 35)
Number of subjects: 70
Study: 9791789

Group type: EXPERIMENTAL
Intervention: Sonicare sonic toothbrush
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interplak counterrotational mechanical toothbrush
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 30
Study: 7617237

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 3 mu/kg/min, started before anesthesia and modulated during the operation based on monitoring values.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no dobutamine infusion), underwent the same anesthesiological procedure without receiving the drug.
Number of subjects: 186
Study: 1978487

Group type: EXPERIMENTAL
Intervention: Controlled release (CR) 400 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate release (IR) 200 mg twice daily
Number of subjects: 24
Study: 629176

Group type: EXPERIMENTAL
Intervention: Laboratory examinations
Number of subjects: 63

Group type: COMPARATOR
Intervention: Written examinations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Laboratory and written examinations
Number of subjects: 63
Study: 6818039

Group type: EXPERIMENTAL
Intervention: Chlordemethyldiazepam (19.25 micrograms/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chlordemethyldiazepam (Cl‐DMDZ)
Number of subjects: 11
Study: 31002399

Group type: EXPERIMENTAL
Intervention: Transfusion of autologous, leukoreduced RBCs after 1, 2, 3, 4, 5, or 6 weeks of storage
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Technetium‐99m‐labeled RBCs infused
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Chromium‐51 PTR method
Number of subjects: 52
Study: 29401353

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; full-dose (two 20-min sessions per day) and half-dose (one 20-min session per day) groups.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; full-dose group vs half-dose group.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; assessed at 30 days post-intervention.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice; assessed at 90 days post-intervention.
Number of subjects: 46
Study: 27384031

Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin aspart (IDegAsp)
Number of subjects: 0
Study: 24476772

Group type: EXPERIMENTAL
Intervention: Galactose (Gal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose (Glu)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22427850

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anemic mothers
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished mothers
Number of subjects: 640
Study: 19778808

Group type: EXPERIMENTAL
Intervention: L-thyroxine (6.25-25 microg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study: 17643226

Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cerebral computed tomographic angiography (CT‐a)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EEG and CT‐a combined (E+C+)
Number of subjects: 21

Group type: COMPARATOR
Intervention: EEG only (E+C(‐))
Number of subjects: 21
Study: 15908661

Group type: EXPERIMENTAL
Intervention: GemOx (gemcitabine 1 g/m2 as a 100‐minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2‐hour infusion on day 2 every 2 weeks)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Gem (gemcitabine 1 g/m2 as a weekly 30‐minute infusion)
Number of subjects: 326
Study: 12039487

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 microM (in vitro)
Number of subjects: 0
Study: 9617916

Group type: EXPERIMENTAL
Intervention: Bromocriptine (DA agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenfluramine (serotonin agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7716629

Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Orthopedic physicians
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 686
Study: 2776043

Group type: EXPERIMENTAL
Intervention: Physical abuse scenario
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Neglect scenario
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gender of subjects
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Age of subjects
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Perception of mistreatment
Number of subjects: 144
Study: 144842

Group type: EXPERIMENTAL
Intervention: SH B 209 AB (antiandrogen preparation containing cyproterone acetate)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Neogynon (ovulation inhibitor with no antiandrogenic effect)
Number of subjects: 88
Study: 30563431

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HIIT (high-intensity interval training)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 42
Study: 28866652

Group type: EXPERIMENTAL
Intervention: 5 mg/day folic acid
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day folic acid
Number of subjects: 45
Study: 26521569

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint injection of nerve growth factor (NGF), 0.5 mL each acupoint, once a day for 7 days, 3 sessions total
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous drop of citicoline sodium and intramuscular injection of NGF, treatment for 7 days, 3 sessions total
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Behavior determination scores
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 61
Study: 23793385

Group type: EXPERIMENTAL
Intervention: Pseudoelastic splints
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional fixed-angle braces
Number of subjects: 25
Study: 21041710

Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT)
Number of subjects: 359
Study: 19185560

Group type: EXPERIMENTAL
Intervention: ALN+D5600 (alendronate + 5600 IU vitamin D3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALN+D2800 (alendronate + 2800 IU vitamin D3)
Number of subjects: 0
Study: 16897661

Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruption (STI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: ALVAC-HIV vCP1452 immunization
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: STI and ALVAC-HIV vCP1452 immunization
Number of subjects: 97
Study: 15633813

Group type: EXPERIMENTAL
Intervention: Acupuncture on the extra 1 point (yintang) for 15 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acupuncture on the control point (2 cm lateral to the end of the right eyebrow) for 15 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acupuncture on the extra 1 point (yintang)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acupuncture on the control point (2 cm lateral to the end of the right eyebrow)
Number of subjects: 50
Study: 11818305

Group type: EXPERIMENTAL
Intervention: Incentive sites (programs with incentives)
Number of subjects: 2402

Group type: COMPARATOR
Intervention: No-incentive sites (programs without incentives)
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Incentive sites
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Phone counseling
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Group programs
Number of subjects: 2402
Study: 9658344

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression with calcific deposits left untouched
Number of subjects: 50
Study: 7651473

Group type: EXPERIMENTAL
Intervention: Myoblast transfer (110 million cells injected once a month for six months)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Myoblast transfer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham injection (control)
Number of subjects: 12
Study: 2487532

Group type: EXPERIMENTAL
Intervention: 150 mg of ibopamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 355879

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy and intermittent positive-pressure breathing with racemic epinephrine every four hours
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (standard care without chest physiotherapy and intermittent positive-pressure breathing)
Number of subjects: 54
Study: 31595716

Group type: EXPERIMENTAL
Intervention: Second-look procedure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Transoral surgery (TOS) alone
Number of subjects: 51
Study: 28872917

Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27046443

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence angiography (ICG-FA) with SPY Elite
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no ICG-FA images viewed)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Skin/subcutaneous hypoperfusion on ICG-FA
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Flap modification after viewing ICG-FA images
Number of subjects: 95
Study: 25044423

Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glyburide therapy
Number of subjects: 8
Study: 21542122

Group type: EXPERIMENTAL
Intervention: High-dose intravenous n-acetylcysteine (1,200 mg bolus followed by 200 mg/hr for 24 hr; n = 206)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo (n = 192)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: High-dose intravenous n-acetylcysteine
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 19595348

Group type: EXPERIMENTAL
Intervention: Synbiotic2000 Forte (n=399)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Control (n=396)
Number of subjects: 795
Study: 17322148

Group type: EXPERIMENTAL
Intervention: CS-706
Number of subjects: 130
Study: 15080606

Group type: EXPERIMENTAL
Intervention: Positive pressure valve device
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard device
Number of subjects: 153
Study: 11467630

Group type: EXPERIMENTAL
Intervention: 50 mg erythromycin (Er50)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg erythromycin (Er100)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study: 9812643

Group type: EXPERIMENTAL
Intervention: Xianzhen tablet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7959083

Group type: EXPERIMENTAL
Intervention: Vitamin C, 250 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo, one capsule twice daily
Number of subjects: 48
Study: 3652479

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg orally at 2200 and 2400 h)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29617737

Group type: COMPARATOR
Intervention: 200 µg/kg ivermectin
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: 600 µg/kg ivermectin
Number of subjects: 292
Study: 26826329

Group type: EXPERIMENTAL
Intervention: Bulk dentine replacement material
Number of subjects: 72

Group type: COMPARATOR
Intervention: Incrementally placed hybrid composite
Number of subjects: 72
Study: 24913256

Group type: EXPERIMENTAL
Intervention: EGA‐Cycling (Environmental Google Street View Based Audit ‐ Cycling to school)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EGA‐Cycling
Number of subjects: 52

Group type: COMPARATOR
Intervention: On‐site assessments
Number of subjects: 52
Study: 22302652

Group type: EXPERIMENTAL
Intervention: HBV screening
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Knowledge of HBV, family and physician recommendations
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Living in the US for more than a quarter of their lifetime
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Having a regular physician
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Doctor's recommendation
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 877
Study: 20863389

Group type: EXPERIMENTAL
Intervention: 40 mg/m² Cisplatin (group I; 16 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 50 mg/m² Paclitaxel (group II; 15 patients)
Number of subjects: 31
Study: 18395723

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (135 mg daily for 6 months)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 16320434

Group type: EXPERIMENTAL
Intervention: Living with a sexual partner
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Living with family or friends
Number of subjects: 245

Group type: COMPARATOR
Intervention: Being responsible for children or others
Number of subjects: 245
Study: 14551299

Group type: COMPARATOR
Intervention: Standard timed (ST) doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Circadian timed (CT) doxorubicin 60 mg/m2 at 6:00 am plus cisplatin 60 mg/m2 at 6:00 pm
Number of subjects: 342
Study: 10827336

Group type: EXPERIMENTAL
Intervention: Baggy condom
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard condom
Number of subjects: 104
Study: 8880110

Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 1 (rapid inspiration with a 2 s end‐inspiratory breathhold)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 2 (rapid inspiration without an end‐inspiratory breathhold)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Manoeuvre No. 3 (slow inspiration lasting about 5 s with an end‐inspiratory breathhold of at least 4 s)
Number of subjects: 25
Study: 1539514

Group type: EXPERIMENTAL
Intervention: Nonionic, low‐osmolar iohexol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ionic, low‐osmolar ioxaglate meglumine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ionic, high‐osmolar meglumine diatrizoate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intracoronary papaverine (10 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin (200 micrograms)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 22
Study: 4033706

Group type: EXPERIMENTAL
Intervention: High-protein diet (268 g per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-protein diet (19 g per day)
Number of subjects: 6
Study: 31908102

Group type: EXPERIMENTAL
Intervention: Mind map-based life review programme (MBLRP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 84
Study: 30567532

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 176
Study: 27565437

Group type: EXPERIMENTAL
Intervention: adolescent text only
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: adolescent and caregiver text plus communication
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: adolescent application only
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: adolescent and caregiver application plus communication
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: epilepsy application for adolescents only
Number of subjects: 25
Study: 26448506

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MECC
Number of subjects: 102

Group type: COMPARATOR
Intervention: ONCAB
Number of subjects: 102
Study: 23897038

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg/kg of body weight twice daily)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: combined genotypes (HTR3A/HTR3B and SLC6A4‐LL/TT)
Number of subjects: 283
Study: 21560011

Group type: EXPERIMENTAL
Intervention: Coached pushing during the second stage of labor
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-coached pushing during the second stage of labor
Number of subjects: 128
Study: 18201285

Group type: EXPERIMENTAL
Intervention: Fractionated plasma separation and adsorption (FPSA)
Number of subjects: 4

Group type: COMPARATOR
Intervention: High flux hemodialysis (HD)
Number of subjects: 4